Among patients with SARS-CoV-2 pneumonia, approximately 20% have an acute kidney injury (AKI) and 5% require renal replacement therapy. Occurrence of AKI in patients with COVID-19 is associated with increased morbidity and mortality. Early detection of patients at risk of AKI would allow to prevent onset or worsening of AKI. The aim of this study is to determine if urine biomarkers of renal tubular damage such as TIMP-2 and IGFBP7 could early identify patients with SARS-CoV-2 pneumonia at risk of developing AKI.
Study Type
OBSERVATIONAL
Enrollment
100
\[TIMP-2\]\*\[IGFBP-7\] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
Uhmontpellier
Montpellier, France
Sensibility and specificity of urinary
Sensibility and specificity of urinary \[TIMP-2\]\*\[IGFBP-7\] \> 0,3 to predict AKI (KDIGO stage ≥ 1) in SARS-CoV-2 patients at day-7 after measurement
Time frame: Occurence of AKI 7 days after urinary biomarkers measurement
Sensibility and specificity of urinary
Sensibility and specificity of urinary \[TIMP-2\]\*\[IGFBP-7\] \> 0,3 to predict AKI worsening, renal replacement therapy requirement or persistant AKI
Time frame: Occurnce of AKI worsening, renal replacement therapy requirement or persistant AKI, 7 days after urinary biomarkers mesurement
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.